Jun. 18 at 10:05 PM
$TOVX VOTE YES ... Clearing the immediate capital structure overhang and going-concern risk. Approving the warrant issuance brings in ~
$8.7 million in fresh cash at
$0.54 per share, which extends the runway and removes the urgent threat of running out of money or being forced into even worse dilution. This allows management to shift focus from survival mode to advancing the VCN-01 clinical programs and pursuing partnerships (especially with companies like AstraZeneca that now have peer-reviewed evidence their drug works better with VCN-01). Removing the repeated failed-vote uncertainty often leads to short covering, reduced selling pressure, and a relief rally as the stock is no longer trading under constant dilution fears. While it is dilutive, it is viewed as a "known" and controlled dilution versus the unknown alternative of continued cash burn and potential bankruptcy risk. Many micro-cap biotech stocks see meaningful rebounds once the financing overhang is resolved.
